What role can disease foundations play in moving scientific discoveries from the lab toward meaningful solutions for patients?In this episode, host Elaine Hamm, PhD, sits down with Tim Coetzee, PhD, President and CEO of the National Multiple Sclerosis Society, to explore how disease foundations can help shape the research and innovation ecosystem. Tim shares the Society’s evolution from funding its first research grants nearly 80 years ago to connecting scientists, clinicians, policymakers,

Planetterrian Daily🌍 Planetterrian Daily - Science, Longevity & Health Discoveries Petal windows in flowers transmit more ultraviolet and infrared radiation, warming interiors and reducing microbial abundance. Top 15 Science & Health Discoveries Petal windows alter light and heat in flowers — Phys.org Some flowers have small semitranslucent sections in their petals. ... Sources: phys.org · sciencedaily.com · nature.com · bjo.bmj.com AI Disclosure: This podcast is curated by Patrick but uses

Cardiovascular disease remains the world's leading cause of death, yet many patients still face substantial risks even after conventional factors such as LDL cholesterol and blood pressure are controlled. Rezera is developing its experimental therapy ruvonoflast, an NLRP3 inhibitor, to address this residual inflammatory risk. The therapy is designed to suppress chronic, tissue-based inflammation while preserving the immune system's ability to respond to infection. Rezera CEO Geoff McDonough

AI safety researcher Roman Yampolskiy breaks down his P(doom) estimate and why he believes artificial superintelligence could be a death sentence for humanity if development keeps moving this fast. His warning isn't anti-AI — it's a case for keeping AI as a tool we control, not a replacement for human judgment.Watch the full episode: https://open.spotify.com/episode/2R7oKzVSOWTR5079TYrZsg?si=302dfca33e9f4c04

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comEpisode SummaryPaul Booth, sports nutritionist, exercise physiologist and PhD researcher in ultra-running metabolism, is back on Mikkipedia, straight from UTMB week in Chamonix, where he raced OCC and worked with elite athletes. Mikki and Paul pick up where they left off a year ago, talking about how much carbohydrate trail and ultra runners actually need. Paul shares

We were delighted to be joined by two highly experienced leaders in the biotechnology industry, Howard Berman, Ph.D., and Kia Motesharei, Ph.D.Both Howard and Kia have built impressive careers across biotechnology, capital markets, business development and strategic transactions, with a track record of helping companies navigate some of the most important stages of their growth.Howard is now CEO of ReAlta Life Sciences, where he is leading the company through an important clinical-stage period as it

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments.In a new pharmaphorum podcast, host Nicole Raleigh speaks with Jason Smith, CTO of AI and analytics at Within3, for a conversation on data-fuelled agile launches and smarter decision-making. Smith discusses alignment of cross-functional teams and fostering real collaboration and efficiency, how pharma teams can use real-time data to shape more precise and effective launch strategies,

The scarecrow watches over the field, but does it watch us back? Does it keep the birds away, or does it deter darker fiends from these haunted lands? Join Robert and Joe for a Halloween-season look at the science, culture and folklore of scarecrows.See omnystudio.com/listener for privacy information.

Michael speaks with Tim Wu, the Columbia law professor and author of The Age of Extraction, about how media and tech platforms learned to harvest our attention, why convenience is among the most powerful forces of our time, and what the easy option can take from us. They discuss:(00:00) Cold open(01:12) Selling attention, from 1833 to now(07:46) Why phones are changing human evolution(16:20) Why ads adapt to every backlash(18:00) Attention merchants vs. extractors(25:48) Easiest wins: the power of

We’re all aware – and wary – of doomscrolling. Lots of screen time can be bad for us. But what if that’s not always the case? We spoke with the author of a study that found a positive relationship between screen time and brain development in young people. This episode, we sort through what to actually worry about when it comes to screen time – and what guidelines already exist that can empower you and the kids in your life.Interested in learning more about how screen time affects your brain? Email

The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight orobesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived

Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare

Carla Rothlin joins Immune at AAI2026 to talk about her career studying inflammation regulation and how she co-founded the Global Immunotalks virtual seminar series. Host: Cindy Leifer Guest: Carla Rothlin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server TAM receptor signaling in immune homeostasis (Annu Rev Immunol, 2015) MerTk in retinal pigment epithelial cells (Sci Adv, 2023) Modifiers determine MerTk function (Elife,

You've perfected your process at the bench. Now comes the part that keeps CMC scientists up at night: will it still work at 2,000L? Right now, most teams find out the hard way, through failed runs, wasted batches, and months of delay to patients waiting on a therapy. Christian Witz believes there's a better way: use computational fluid dynamics to see how your cells will actually behave at full scale before you ever run the process, and stop treating scale-up as a guessing game. On this episo...

In this special episode, in partnership with Frontiers Science House, we launch our new Why? series by asking one of the biggest questions of our time: Why AI? Why has artificial intelligence advanced so rapidly, why does it work the way it does, and why could it fundamentally change how we think, work, and live? To explore the answers, we hear from four remarkable voices at the heart of the AI conversation: Geoffrey Hinton, Mike Wooldridge, Cristina Criddle, and Wendy Hall. Like this podcast

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the preceden...

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

What is the state of the debate over evolution and intelligent design in the UK? And how will Discovery Institute's new Cambridge initiative impact the debate going forward? On this ID The Future, host Andrew McDiarmid welcomes fellow Scotsman Dr. Alistair McKitterick, a Consulting Fellow at the Center for Science & Culture’s Whewell Center in Cambridge and a Program Director at London School of Theology. The pair will discuss how Alistair got interested in intelligent design, his work at the

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.

Each week, join Editor-in-Chief Brad Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, Brad and Merci welcome our own Jane Wilcox to discuss a new article type in Circulation: Clinical Problem-Solving. She also discusses her own Clinical Problem-Solving article "When VT Storm, PET Positivity, and a Negative Endomyocardial Biopsy Collide." Then Brad and Merci speak with Associate Editor Maria Kontaridis as she discusses her